Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 5/20 | 0.47 |
| ▸ | CYP4A11 | Q02928 | 5/20 | 0.47 |
| ▸ | ATR | Q13535 | 12/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | RXRA | P19793 | 1/20 | 0.39 |
| ▸ | RXRB | P28702 | 1/20 | 0.39 |
| ▸ | RXRG | P48443 | 1/20 | 0.39 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3041585 | 0.88 | CYP4F2 (0.40) | CYP4F2CYP4A11ATRALDH1A1LMNA | |
| SCHEMBL29987315 | 0.79 | CYP4F2 (0.36) | CYP4F2CYP4A11ATRRXRARXRB | |
| SCHEMBL1649419 | 0.78 | CYP4F2 (0.41) | CYP4F2CYP4A11ATRRXRARXRB | |
| SCHEMBL30739025 | 0.78 | CYP4F2 (0.44) | CYP4F2CYP4A11ATRALDH1A1LMNA | |
| SCHEMBL2839522 | 0.77 | CYP4F2 (0.42) | CYP4F2CYP4A11ATRALDH1A1LMNA | |
| SCHEMBL29953278 | 0.77 | PKM (0.40) | ALDH1A1LMNA | |
| SCHEMBL24173879 | 0.76 | ALDH1A1 (0.49) | CYP4F2CYP4A11ATRALDH1A1LMNA | |
| SCHEMBL18438313 | 0.76 | CYP4F2 (0.50) | CYP4F2CYP4A11ATRALDH1A1LMNA | |
| SCHEMBL8004755 | 0.76 | CYP4F2 (0.53) | CYP4F2CYP4A11ATRALDH1A1LMNA | |
| SCHEMBL18133767 | 0.76 | CYP4F2 (0.47) | CYP4F2CYP4A11ATRALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12391675-B2 | NLRP3 modulators | INNATE TUMOR IMMUNITY, INC. (US) | 2025-08-19 | — | — | US | disclosed |
| US-12338228-B2 | NLRP3 modulators | INNATE TUMOR IMMUNITY, INC. (US) | 2025-06-24 | — | — | US | disclosed |
| US-12171756-B2 | NLRP3 modulators | INNATE TUMOR IMMUNITY, INC. (US) | 2024-12-24 | — | — | US | disclosed |
| EP-3652166-B1 | NLRP3 MODULATORS | INNATE TUMOR IMMUNITY INC (US) | 2024-11-20 | — | — | EP | disclosed |
| US-20240317741-A1 | NAPHTHYRIDINE DERIVATIVE AS ATR INHIBITOR AND METHOD FOR PREPARING SAME | Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) | 2024-09-26 | — | — | US | disclosed |
| WO-2024140851-A1 | TOLL-LIKE RECEPTOR INHIBITOR, AND PREPARATION THEREFOR AND APPLICATION THEREOF | 上海维申医药有限公司 | 2024-07-04 | — | — | WO | disclosed |
| EP-4385992-A1 | NAPHTHYRIDINE DERIVATIVE AS ATR INHIBITOR AND METHOD FOR PREPARING SAME | Wigen Biomedicine Technology (Shanghai) Co., Ltd. (CN) | 2024-06-19 | — | — | EP | disclosed |
| EP-4126855-B1 | COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTIONS | HOFFMANN LA ROCHE (CH) | 2024-04-24 | — | — | EP | disclosed |
| CN-117736222-A | MTA synergistic PRMT5 inhibitor compounds having tricyclic or tetracyclic ring structures | 烨辉医药科技(上海)有限公司 | 2024-03-22 | — | — | CN | disclosed |
| CN-117642401-A | Naphthyridine derivatives as ATR inhibitors and methods of preparing same | 微境生物医药科技(上海)有限公司 | 2024-03-01 | — | — | CN | disclosed |
| US-8314094-B2 | Benzoxazinone derivative | MSD K.K (JP) | 2012-11-20 | — | — | US | disclosed |
| WO-2012126901-A1 | BENZOXAZEPIN COMPOUNDS SELECTIVE FOR PI3K P110 DELTA AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2012-09-27 | — | — | WO | disclosed |
| WO-2012126901-A1 | BENZOXAZEPIN COMPOUNDS SELECTIVE FOR PI3K P110 DELTA AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2012-09-27 | — | — | WO | disclosed |
| US-20120245144-A1 | BENZOXAZEPIN COMPOUNDS SELECTIVE FOR PI3K P110 DELTA AND METHODS OF USE | GENENTECH, INC. (US) | 2012-09-27 | — | — | US | disclosed |
| US-20120245144-A1 | BENZOXAZEPIN COMPOUNDS SELECTIVE FOR PI3K P110 DELTA AND METHODS OF USE | GENENTECH, INC. (US) | 2012-09-27 | — | — | US | disclosed |
| US-20110178064-A1 | SPIRO CONDENSED BARBITURIC ACID DERIVATIVES FOR USE AS ANTIBACTERIAL | ASTRAZENECA R&D (SE) | 2011-07-21 | — | — | US | disclosed |
| US-20100210636-A1 | BENZOXAZINONE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. | 2010-08-19 | — | — | US | disclosed |
| EP-2210880-A1 | BENZOXAZINONE DERIVATIVE | Banyu Pharmaceutical Co., Ltd. (JP) | 2010-07-28 | — | — | EP | disclosed |
| EP-2178876-A1 | SPIRO CONDENSED BARBITURIC ACID DERIVATIVES FOR USE AS ANTIBACTERIAL | AstraZeneca AB (SE) | 2010-04-28 | — | — | EP | disclosed |
| WO-2009010801-A1 | SPIRO CONDENSED BARBITURIC ACID DERIVATIVES FOR USE AS ANTIBACTERIAL | ASTRAZENECA UK LIMITED (GB) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178064-A1 | SPIRO CONDENSED BARBITURIC ACID DERIVATIVES FOR USE AS ANTIBACTERIAL | TBCA, TUBA1A, BROX | CYP4F2 2105/4885CYP4A11 1349/4885ATR 3344/4885 |
| US-12338228-B2 | NLRP3 modulators | NLRP3, NLRP1, PYCARD | CYP4F2 2752/4885CYP4A11 461/4885ATR 2944/4885 |
| US-20240317741-A1 | NAPHTHYRIDINE DERIVATIVE AS ATR INHIBITOR AND METHOD FOR PREPARING SAME | ATR, ATRIP, TBK1 | CYP4F2 4095/4885CYP4A11 2621/4885ATR 1/4885 |
| US-12391675-B2 | NLRP3 modulators | NLRP3, NLRP1, PYCARD | CYP4F2 1820/4885CYP4A11 259/4885ATR 3060/4885 |
| US-20120245144-A1 | BENZOXAZEPIN COMPOUNDS SELECTIVE FOR PI3K P110 DELTA AND METHODS OF USE | PIK3CA, PIK3CD, PIK3R4 | CYP4F2 1652/4885CYP4A11 69/4885ATR 2345/4885 |
| US-20100210636-A1 | BENZOXAZINONE DERIVATIVE | HAX1, CYP4X1, CYP19A1 | CYP4F2 205/4885CYP4A11 50/4885ATR 2978/4885 |
| US-12171756-B2 | NLRP3 modulators | NLRP3, NLRP1, PYCARD | CYP4F2 1583/4885CYP4A11 242/4885ATR 3043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.